Clinical trials
Welcome to the Amyloidosis Clinical Trials page!
This page is designed to be easy to understand for both patients and clinicians alike.
Clinical trials are subdivided into major amyloidosis types: ATTR, AL and Other.
Please SCROLL DOWN for full details.
Clinical trials are listed here once the first health service in Australia has fully opened the trial for patient enrollment.
Once a trial has been listed as being open (or “activated“) at one site, other sites in Australia selected to participate will also be listed, even thought they may not yet be fully open (“pending“).
Please note : Listing a clinical trial on this website does not necessarily equate as endorsement of the trial by the Australian Amyloidosis Network. Any patient interested in a trial should discuss the pros and cons of the studies with their treating practitioner.
For each trial, a description of the trial, including key inclusion and exclusion criteria, and local contacts are provided.
The trial status at each site will be indicated by a symbol.
The key is as follows:

Trials by State










Use the map at left
to view trials in your state.
Click on each state for location detail.
New South Wales & ACT
AL Trials
Etentamig (ABBV383) M24-209
VIBER-M
ATTR Trials
MAGNITUDE: A Phase 3 study of NTLA-2001
MAGNITUDE-2
CAPACE
Victoria & Tasmania
All Types
Positron Emission Tomography with AT-01
AL Trials
Etentamig (ABBV383) M24-209
APG2575MU101
VIBER-M
ATTR Trials
MAGNITUDE: A Phase 3 study of NTLA-2001
Queensland
All Types
Positron Emission Tomography with AT-01
AL Trials
Etentamig (ABBV383) M24-209
VIBER-M
Development of personalised mRNA vaccines
ATTR Trials
MAGNITUDE: A Phase 3 study of NTLA-2001
Northern Territory
There are currently no trials operating in the Northern Territory
All Types of Amyloid
Positron Emission Tomography with AT-01 : – (open to all types of amyloid).
- Positron Emission Tomography with AT-01 to Diagnose and Monitor Amyloidosis: A Prospective Cohort Pilot Study in Adult Patients.
- ACTRN12624000755538
What is the drug in question?
AT-01 is a novel peptide radiotracer which binds to a constant region of the insoluble amyloid protein; the agent which results in end-organ damage in amyloidosis. It is able to demonstrate on molecular imaging scans the presence of amyloid within all vital organs of the body, namely the heart, kidneys, liver and spleen. No other imaging modality has been able to capture this in a single scan. By accurately detecting amyloid in organs of the body and assessing for response to therapy, AT-01 PET/CT scans have the potential to revolutionise the way amyloidosis is diagnosed, monitored, and help to guide treatment decisions in the future.
Who is eligible for the trial?
- Newly diagnosed systemic amyloidosis – all subtypes
- Systemic AL amyloidosis with suboptimal response to therapy or in early biochemical relapse.
Does every patient receive the actual trial drug?
Yes
How is the drug administered?
The drug is given through an IV (drip into the vein).
How long does the trial go for?
2 years
Key inclusion criteria:
- Diagnosis of amyloidosis with the known following subtype:
(a) Systemic AL amyloidosis prior to therapy commencement (n=15)
(b) Systemic AL amyloidosis with suboptimal response to therapy or in early biochemical relapse (n=5)
(c) ATTRwt amyloidosis (n=5)
(d) Other systemic amyloidosis i.e. ALECT2 and Alys amyloidosis (n=5) - Age equal to or greater than 18yrs
- Life expectancy greater than 3 months
Key exclusion criteria:
Subjects must meet none of the following criteria:
- Localised amyloidosis
- Known iodine or potassium iodide hypersensitivity
- Patients being treated with heparin and heparin like anticoagulant therapy (due to interaction with AT-01)
- Patients who are pregnant and/or breastfeeding
Sites
Victoria
Status: | |
Site: | Eastern health (Box Hill Hospital), Melbourne |
Contact: | Dr Brendan Wisniowski Brendan.Wisniowski@easternhealth.org.au |
Queensland
Status: | |
Site: | Princess Alexandra Hospital |
Contact: | Amyloidosis@health.qld.gov.au |
Patients will have access to clinical trial data
Systemic Light Chain Amyloidosis (AL) trials
Newly diagnosed:
None current.
Previously treated:
Study Summary
ABBV-383: Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. AL amyloidosis has many root causes and is characterized by the overproduction of AL that are secreted by clonal bone marrow plasma cells. This is a study to determine adverse events and change in disease activity in adult participants with AL amyloidosis treated with ABBV-383.
ABBV-383 is an investigational drug being developed for the treatment of AL amyloidosis. This study in broken into 2 parts (dose escalation and safety expansion) with 5 arms. During dose escalation (arms 1-3) participants will receive 1 of 3 doses of ABBV-383 to determine the part 2 doses. After completion of the dose escalation portion of the study, the safety expansion (part 2) portion of the study will begin. Two arms (arm 4-5) will begin and participants will receive 1 of 2 doses as determined during the dose escalation portion (part 1). Around 76 adult participants with relapsed/refractory AL amyloidosis will be enrolled at approximately 20 sites across the world.
Participants will receive ABBV-383 as an infusion into the vein for up to approximately 2 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.
Who is eligible for the trial?
Patients with relapsed or refractory systemic AL amyloidosis who have previously been treated with bortezomib and daratumumab.
Does every patient receive the actual trial drug?
All patients receive ABBV-383.
How is the drug administered?
After an initial dose step up phase ABBV-383 is given as a subcutaneous injection every 28 days.
How long does the trial go for?
The treatment continues for 2 years in an estimated 76 patients. The trial will continue to watch the response in patients for a number of years after the treatment finished.
Key inclusion criteria:
- Diagnosis of primary systemic immunoglobulin light chain (AL) amyloidosis.
- Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.
- Have at least 1 organ historically impacted by AL amyloidosis.
- Considered AL amyloidosis risk stage 1, 2, or 3a and have measurable disease of AL amyloidosis as defined by difference between involved and uninvolved free light chains (dFLC) >= 50 mg/L.
- Has previously been exposed to a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.
Key exclusion criteria:
Subjects must meet none of the following criteria:
- Known history of clinically significant (per investigator’s judgment) drug or alcohol abuse within the last 6 months.
- Known allergic reaction, significant sensitivity, or intolerance to constituents of the study drugs (and excipients) and/or other products in the same class.
- Participant has the following conditions:
- Other non-AL amyloid disease;
- Previous or current diagnosis of symptomatic multiple myeloma (MM), including the presence of lytic bone disease, plasmacytomas, >= 60% plasma cells in the bone marrow, or hypercalcemia (defined as corrected calcium > 11 mg/dL);
- Active plasma cell leukemia (i.e., either 20% of peripheral white blood cells or > 2.0 × 109/L circulating plasma cells by standard differential);
- Waldenström’s macroglobulinemia;
- Acute diffuse infiltrative pneumopathy;
- Major surgery within 28 days prior first dose or planned during study participation;
- History of organ transplant requiring continued use of immunosuppressants;
- Acute infections within 14 days prior first dose requiring parenteral therapy (antibiotic, antifungal, or antiviral);
- Participant has received an autologous stem cell transplant (SCT) within 12 weeks or an allogeneic SCT within 1 year of the first dose of study drug treatment.
For more information, please contact one of the three recruiting centres in Australia, or USE THIS LINK
Sites
New South Wales
Status: | |
Site: | Westmead Hospital, Sydney |
Contact: | Dr Fiona Kwok WSLHD-WAC-Correspondence@health.nsw.gov.au |
Queensland
Status: | |
Site: | Princess Alexandra Hospital, Brisbane |
Contact: | Dr Peter Mollee Amyloidosis@health.qld.gov.au |
Victoria
Status: | |
Site: | Eastern health (Box Hill Hospital), Melbourne |
Contact: | Dr Olga Motorna olga.motorna@easternhealth.org.au |
A Phase Ib/II study of Venetoclax, IBERdomide and dexamethasone for patients in first or
second relapse of Multiple myeloma and/or systemic AL amyloidosis with t(11;14)
What is the drug in question?
Iberdomide is a “CelMod”, which is similar to lenalidomide and pomalidomide. It is well tolerated with proven activity in myeloma.
It is hoped that iberdomide to be more effective and less toxic than lenalidomide in the treatment of AL amyloidosis.
Venetoclax, a BCL2 inhibitor, which used in many haematological conditions, but in myeloma and AL amyloidosis, venetoclax specifically targets the effects of t(11;14) mutation.
Who is eligible for the trial?
- Patients with AL amyloidosis who have relapsed after 1 or 2 lines of treatment previously.
- Patients must have have the t(11;14) translocation (genetic variation) detected on their bone marrow biopsy (seen in ~50% of all AL amyloidosis patients).
- Patients must have serum free light chains (SFLC) >100mg/L to qualify
How is the drug administered?
This clinical trial is designed to see if the combination of both medications with the steroid, dexamethasone, has very high response rate, has quicker response times and is well tolerated.
This is an Australian only study of 50 patients.
Note that this treatment is an all oral (tablet) treatment.
You will be given medication to minimise the risk of these side-effects.
How long does the trial go for?
The three medications will continue until it stops working or if the patient has significant sideeffects and/or wants to withdraw from the study.
While this combination is expected to be well tolerated, the more common potential sideeffects of this treatment are low blood counts, rash, infections and clots.
Sites
Victoria
Status: | |
Site: | Eastern health (Box Hill Hospital), Melbourne. |
Contact: | Olga Motorna and Stephen Ting Email: olga.motorna@easternhealth.org.au |
Status: | |
Site: | St Vincent’s Hospital, Melbourne. |
Contact: | Shirlene Sim and Hang Quach Email: shirlene.sim@svha.org.au |
Queensland
Status: | |
Site: | Townsville University Hospital |
Contact: | Hock Choong Lai Email: hock.lai@health.qld.gov.au |
New South Wales
Status: | |
Site: | Gosford Hospital |
Contact: | Cecily Forsyth Email: cecily.forsyth@healthmail.com.au |
Status: | |
Site: | Royal North Shore, Sydney |
Contact: | Ian Kerridge Email: ian.kerridge@health.nsw.gov.au |
Status: | |
Site: | Liverpool Hospital |
Contact: | Adam Bryant Email: adam.bryant1@health.nsw.gov.au |
South Australia
Status: | |
Site: | Royal Adelaide Hospital |
Contact: | Elizabeth Tucker Email: elizabeth.tucker@sa.gov.au Angie Yong Email: Angie.Yong@sa.gov.au |
APG-2575 (varying doses) + pomalidomide and dexamethasone (Pd)
What is the drug in question?
Approximately 50% of patients with AL amyloidosis have a chromosomal (genetic) change involving part of chromosome 11 swapping with part of chromosome 14, referred to as “t(11;14)”. BCL-2 inhibitors target this mutation and can cause cell death of the plasma cells that make the amyloid. APG-2575 is a novel BCL-2 inhibitor.
In this study, APG-2575 is combined with pomalidomide, an immunomodulatory drug which has been used extensively in myeloma, and appears to be effective and well tolerated in AL amyloidosis too. Dexamethasone, a steroid, is also combined with APG-2575 and pomalidomide, to hopefully enhance the effect of the drug.
During the study, patients will be assigned different doses of APG-2575 to determine the highest dose that is the best tolerated.
Who is eligible for the trial?
Any patient with relapsed AL amyloidosis with organ involvement (eg. heart and/or kidneys), or a patient who has not achieved an excellent response to their first 3 cycles of front-line chemotherapy.
Does every patient receive the actual trial drug?
Yes, all patients receive APG-2575, pomalidomide and dexamethasone
How is the drug administered?
This is an all oral, tablet treatment
How long does the trial go for?
Patients will continue to receive treatment until disease progression, unacceptable toxicity, or withdrawal of consent.
Key inclusion criteria:
Systemic AL (not ATTR) amyloidosis, involving the heart, as proven by
- ≥ 18 years of age.
- Histochemical diagnosis based on detection by polarizing microscopy of green birefringent material in Congo red-stained tissue specimens, the type must have been confirmed unequivocally.
- Symptomatic organ involvement.
- At least one prior line of systemic therapy for AL. Patients who do not achieve at least a PR to frontline therapy in 3 months are eligible.
- All MM/AL patients should have measurable disease as defined by at least ONE of the following:
- Serum monoclonal protein 1.0 g/dl or more by protein electrophoresis.
- >200 mg of monoclonal protein in the urine on 24-hour electrophoresis.
- If both serum and urine monoclonal proteins are non-measurable:
- Serum differential FLC concentration (dFLC) > 5 mg/dL; OR serum FLC of 7.5 mg/dL provided the κ/λ FLC ratio is abnormal
- Eastern Cooperative Oncology Group (ECOG) ≤ 2.
- Life expectancy ≥ 6 months.
- Adequate hematologic function defined as:
- ANC ≥1.0 x 109/L independent of growth factor support within 7 days of the first dose with study drug.
- Haemoglobin ≥8 g/dL without transfusion or growth factor support within 7 days of the first dose of study drug.
- Platelet count ≥ 100 x 109/L or ≥ 50 x 109/L if bone marrow involvement independent of transfusion support
- Adequate hepatic and renal function defined as:
- AST and ALT < 3 x upper limit of normal
- Creatinine ≤3 mg/dL and CrCL ≥25 ml/min using the Cockcroft-Gault formula
- Bilirubin< 1.5 x ULN (except if considered secondary to Gilbert’s syndrome and primarily indirect bilirubinemia)
- PT/INR ≤2 x ULN and PTT (or aPTT) ≤2 x ULN.
- Female subjects who are of non-reproductive potential. Female subjects of childbearing potential must have a negative serum pregnancy test upon study entry.
- Male and female subjects who agree to use highly effective methods of birth control during the period of therapy and for 90 days after the last dose of study drug.
- Ability to cooperate to complete neurological examinations if required
Key exclusion criteria:
- AL amyloidosis patients who have not been treated with any systemic therapy
- AL amyloidosis clinically overt multiple myeloma i.e. original CRAB criteria. Extent of marrow plasmacytosis is not prohibitive.
- Subject has received antineoplastic therapy within 2 weeks before the date of initiating study treatment.
- Subjects planning to undergo a stem cell transplant prior to progression of disease on this study, i.e., these subjects should not be enrolled in order to reduce disease burden prior to transplant.
- Subject has peripheral neuropathy ≥grade 3 except caused by AL amyloidosis.
- Active cardiovascular disease, such as uncontrolled arrhythmia (including Frederica corrected QT interval (QTc ≥470 msec) or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction or unstable angina.
- Major surgical procedure within ≤14 days prior to initiating study treatment, or anticipation of the need for major surgery during the course of the study treatment, radiotherapy ≤14 days prior to initiating study treatment, systemic treatment within 14 days before the first dose of APG2575.
- Recent infection requiring systemic treatment that was completed ≤14 days before the first dose of study drug.
- Subject has any concurrent or recent malignancy ≤ 1 year prior to registration with the exception of: basal or squamous cell skin cancer, any carcinoma in situ.
ACCESS CLINICAL TRAILS DATABASE HERE
Sites
Victoria
Status: | |
Site: | Epworth Freemasons, Melbourne |
Contact: | Dr Brendan Wisniowski Ph: 03 8560 4010 |
Correlative research:
Study Summary
- Immunoglobulin light chain (AL) amyloidosis is the most common form of systemic amyloidosis. Abnormal clonal bone marrow plasma cells secrete AL that cause a host of systemic effects. Current treatments focus on the eradication of these abnormal plasma cells but are unable to differentiate between normal and abnormal plasma cells.
- This biomedical lab study aims to stimulate a patient’s immune system to only target the abnormal plasma cells that cause their disease. This study will look at the efficacy of personalised mRNA vaccines in-vitro.
Who is eligible for the trial?
Participants with suspected, confirmed or relapsed/refractory AL amyloidosis, who are currently not on treatment.
What do patients need to do?
For this biomedical lab study, bone marrow aspirate and peripheral blood are required from participants. No other participation is required.
How long does the trial go for?
This study will run for 3 years.
Anything else I need to know?
As this is a lab study, there will be no treatment offered to participants. The samples collected from participants will confirm if our approach is applicable for patients with AL amyloidosis. We hope this study will inform future clinical trials that offer personalised mRNA vaccines for patients with AL amyloidosis and related disorders.
Sites
Queensland
Status: | |
Site: | Princess Alexandra Hospital, Brisbane |
Contact: | Muhammed B. Sabdia m.bilalsabdia@mater.uq.edu.au |
Please check this website weekly for updates!
Transthyretin Amyloidosis (ATTR) trials
Please click on the links below for more details.
What is the drug in question?
NTLA-2001- clustered regularly interspaced short palindromic repeats (CRISPR) of RNAs encoding protein 9 (Cas9) formulated in lipid nanoparticle for IV use.
What does the study hope to prove?
Safety and efficacy of editing (removing) gene responsible for TTR synthesis.
Who is eligible for the trial?
Subjects with ATTR cardiomyopathy.
Does every patient receive the actual trial drug?
No. Randomisation is in 2:1 ratio to receive either study drug (2/3) or placebo (1/3).
How is the drug administered?
Single intravenous infusion.
How long does the trial go for?
30 months
Key inclusion criteria:
Male and Female aged 18 to 90 years old with documented ATTR cardiomyopathy who signed the informed consent with history or current symptoms of heart failure and elevated cardiac biomarkers (NTproBNP).
Key exclusion criteria:
- Other non TTR type of Amyloidosis
- Severe heart failure (class 4 NYHA)
- Other significant cardiac cause leading to HF (CAD, valve disease etc)
- Recent (within 3 months) cardiac (heart attack) and non-cardiac (stroke, PE, DVT) event
- End stage liver disease
- Active infection
- Malignancy within preceding 3 years
- Solid organ recipient
Where to go for more information:
See below.
Sites
Victoria
Status: | |
Site: | Eastern health (Box Hill Hospital), Melbourne |
Contact: | Brendan.Wisniowski@easternhealth.org.au |
Queensland
Status: | |
Site: | Princess Alexandra Hospital, Brisbane |
Contact: | Amyloidosis@health.qld.gov.au |
New South Wales
Status: | |
Site: | Westmead Hospital, Sydney |
Contact: | WSLHD-TTRtrials@health.nsw.gov.au |
Australian Capital Territory
Status: | |
Site: | Canberra Hospital |
Contact: | Erin.Clark@act.gov.au and Wichat.Srikusalanukul@act.gov.au |
Western Australia
Status: | |
Site: | Fiona Stanley Hospital |
Contact: | Kaitlyn.Lam@health.wa.gov.au |
South Australia
Status: | |
Site: | Royal Adelaide Hospital |
Contact: | Name: Denise Healy Email: denise.healy@sa.gov.au |
New Zealand
Status: | |
Site: | New Zealand Clinical Research (NZCR) Auckland and Christchurch |
Contact: | Timothy.Sutton@middlemore.co.nz |
What is the drug in question?
ALXN2220 is a recombinant human anti-ATTR antibody that was developed for the removal of ATTR by phagocytic immune cells.
What does the study hope to prove?
Efficacy of ALXN2220 in the treatment od ATTR cardiomyopathy.
Who is eligible for the trial?
Male or Female between 18 and 90 years of age with confirmed ATTR-CM.
Does every patient receive the actual trial drug?
Randomisation is in 2:1 ratio to receive either study drug (2/3) or placebo (1/3).
How is the drug administered?
By intravenous infusion every 4 weeks.
How long does the trial go for?
48 months
Key inclusion criteria:
Subjects with confirmed ATTR-CM, history or current heart failure (class 2-4 NYHA dyspnoea) and elevated cardiac biomarkers (NTproBNP).
Key exclusion criteria:
- Other non TTR types of amyloidosis
- Cardiomyopathy caused by other condition
- Recent (within 3 months) acute CV event
- Low LV ejection fraction (<30%)
- Severe non cardiac medical illness (lung, liver, kidney)
- Malignancy within last 5 years
- Solid organ recipient
- Low body weight (<40kg)
Where to go for more information:
See below.
Sites
Victoria
Status: | |
Site: | Eastern health (Box Hill Hospital), Melbourne |
Status: | |
Site: | The Alfred, Melbourne |
Queensland
Status: | |
Site: | Princess Alexandra Hospital, Brisbane |
Contact: | Amyloidosis@health.qld.gov.au |
New South Wales
Status: | |
Site: | Westmead Hospital, Sydney |
Contact: | WSLHD-TTRtrials@health.nsw.gov.au |
Status: | |
Site: | St Vincent’s Hospital, Sydney |
Western Australia
Status: | |
Site: | Joondalup, Perth |
South Australia
Status: | |
Site: | Flinders Medical Centre |
Contact: | Name: Fiona Wollaston Email: fiona.wollaston2@sa.gov.au |
What is the drug in question?
NTLA-2001- clustered regularly interspaced short palindromic repeats (CRISPR) of RNAs encoding protein 9 (Cas9) formulated in lipid nanoparticle for IV use.
What does the study hope to prove?
Safety and efficacy of editing (removing) gene responsible for TTR synthesis in patients with hereditary ATTR with polyneuropathy.
Who is eligible for the trial?
Subjects with hereditary ATTR with polyneuropathy.
Does every patient receive the actual trial drug?
No. Half of them (50%) will receive placebo. However, after 12-18 months (depending on rate of any progression in nerve disease) participants may choose to receive blinded crossover treatment (either placebo or NTLA-2001) ie what ever they did not receive on the trial initially .
How is the drug administered?
Single intravenous infusion
How long does the trial go for?
This depends on whether the participant chooses to receive the blinded crossover treatment after 12-18 months.
Key inclusion criteria:
Male and Female aged 18 to 85 years old inclusive with hereditary ATTR with polyneuropathy who signed the informed consent who are naive to TTR silencers (siRNAs and ASOs).
Key exclusion criteria:
- Other known causes of sensorimotor or autonomic neuropathy
- Amyloidosis due to a non-TTR protein
- Known leptomeningeal amyloidosis
- Known diabetes mellitus
- Recent (within 3 months) cardiac (heart attack) and non-cardiac (stroke, PE, DVT) event
- End stage liver disease
- Active infection
- Malignancy within preceding 3 years
- Prior receipt of TTR silencer (siRNA or ASO)
- Solid organ recipient
Where to go for more information:
See below.
Sites
New South Wales
Status: | |
Site: | Westmead Hospital, Sydney |
Contact: | WSLHD-TTRtrials@health.nsw.gov.au |
Optimal heart rates in patients with Cardiac Amyloidosis and pacemakers
Study intervention and description of involvement:
- Prospective pilot study of cardiac pacing augmented myocardial dynamics in patients with transthyretin cardiac amyloidosis. The study includes enrolment then two site study visits and a final phone call at 1 year.
- During the first visit a patient will undergo clinical assessment with physical examination, quality of life survey, 6 minute walk test, electrocardiogram (ECG), echocardiogram and cardiac magnetic resonance imaging (CMR) at three different pacing rates, assessing the cardiac response to each heart rate. Cardiac device pacing rate will then be set to the individually optimised pacing rates as per CMR for one month.
- The second visit at one month will include brief physical examination, quality of life survey, 6 minute walk test, electrocardiogram (ECG), echocardiogram. Cardiac devices will be interrogated to confirm the heart rate paced during the prior intervention period and reprogrammed to their original settings.
Patients will receive a brief follow up phone call at 1 year.
Inclusion criteria:
- People who meet diagnostic criteria for transthyretin cardiac amyloidosis
- Cardiac implantable electronic device (pacemakers or defibrillator) which is MRI compatible.
- Underlying native heart rate of 60 beats per minute or less.
- Willingness to give written informed consent and willingness to participate to and comply with the study
Exclusion criteria:
- Patients with any contraindications for CMR imaging including:
- Patients with previous allergy to gadolinium.
- Patients with a history of significant renal impairment (eGFR<30ml/min/1.73m2).
- Patients who are medically unstable.
- Patients with claustrophobia.
- Cardiac pacemakers or implantable cardioverter defibrillator not deemed to be MRI compatible.
- Pregnancy or lactating.
- Orbital foreign bodies from metal injury to the eye.
- Intracranial metal clips.
- Non-MRI compatible stapes implants.
- Programmable Hydrocephalus Shunts.
- Large metal implants.
- Patients with a history of a psychological illness or condition such as to interfere with the patient’s ability to understand the requirements of the study.
Where to go for more information:
Name Dr Natasha Gorrie
Email: natasha.gorrie@svha.org.au
Sites
New South Wales
Status: | |
Site: | St Vincent’s Hospital, Sydney |